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Abstract
Background: Hepatic natural killer (NK) cells, the most cytotoxic cells of the natural occurring
NK cells, are located in the liver sinusoids and are thus in a strategic position to kill arriving
metastasising tumour cells, like colon carcinoma cells. It is known that major histocompatibility
complex (MHC) class I on tumour cells negatively regulates NK cell-mediated cytolysis, but this is
found using blood- or spleen-derived NK cells. Therefore, using isolated rat hepatic NK cells and
the syngeneic colon carcinoma cell line CC531s, we investigated whether this protective role of
MHC class I is also operative in hepatic NK cells, and addressed the mechanism of MHC class I
protection.
Results: When MHC class I on CC531s cells was masked by preincubation with monoclonal
antibody OX18, hepatic NK cell-mediated cytolysis (51Cr release) as well as apoptosis (DNA
fragmentation, nucleus condensation and fragmentation) increased. When hepatic NK cells were
preincubated with the granzyme inhibitor 3,4-dichloroisocoumarin, or when extracellular Ca2+ was
chelated by ethylene glycol-bis(β-aminoethyl ether)-N, N-tetraacetic acid, the enhanced cytolysis
and apoptosis were completely inhibited. The involvement of the perforin/granzyme pathway was
confirmed by showing that the enhanced cytolysis was caspase-independent.
Conclusions: MHC class I expression protects CC531s colon carcinoma cells from hepatic NK
cell-mediated apoptosis and cytolysis, by blocking the perforin/granzyme pathway.
Background
Natural killer (NK) cells are large granular lymphocytes
that have the ability to kill cells without prior sensitisation
and therefore play an important role in host defence [1].
NK cell-mediated target cell killing is mainly implement-
ed by two pathways, namely the perforin/granzyme path-
way and the Fas ligand (FasL) pathway [2–5]. In the latter
pathway, FasL on effector cells binds Fas present on the
target cells which results in oligomerization of Fas and ac-
tivation of caspase 8. Perforin and granzymes, of which
granzyme B is the most potent one, reside in the granules
of NK cells and are released by exocytosis after conjuga-
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tion between the effector and target cell [4,5]. Inside the
cytoplasm of the target cell, granzyme B activates caspase
3 directly [6] or indirectly, via a mitochondrion-depend-
ent pathway [7]. Caspases play an essential role in the ex-
ecution of apoptosis [6].
NK cells display two types of surface receptors: (i) activa-
tion receptors, such as the CD161 molecule that recognis-
es structures on target cells and triggers NK cells to kill; (ii)
inhibitory receptors, such as Ly-49 molecules, that recog-
nise target cell MHC class I molecules and inhibit killing
by NK cells [8,9]. When MHC class I molecules are absent
or expressed in reduced amounts, the NK cells proceed
with their attack [10]. The mechanism of MHC class I pro-
tection is not fully understood. MHC class I molecules do
not block target cell recognition by NK cells [11]. A recent
study shows that H-2Dd MHC class I molecules on target
cells partially inhibit granzyme A release from mouse Ly-
49A+ NK cells [12]. However, it is unclear whether such
partial inhibition of granzyme A release is sufficient to
protect target cells. Moreover, the assay used in the past to
detect cytotoxicity by cytolysis is the release of 51Cr from
loaded target cells. A recent study questioned the rele-
vance of the 51Cr release assay compared to what occurs in
vivo, whereas the DNA fragmentation assay to measure ap-
optosis coincided with in vivo results [13]. Therefore, it is
needed to explore whether the protective role of MHC
class I is also operative in apoptosis induced by NK cells.
Compared with NK cells from spleen and peripheral
blood, hepatic NK cells, also called pit cells [14], are much
more cytotoxic [15,16]. Strategically located in the liver si-
nusoids, they constitute a first line of cellular defence
against invading cancer cells, like colon carcinoma cells
[15,17–20]. In this study, using freshly isolated hepatic
NK cells and CC531s, a syngeneic Fas ligand-resistant co-
lon carcinoma cell line [21], we (i) demonstrated that
MHC class I protects colon carcinoma cells from hepatic
NK cell-mediated killing; and (ii) showed the involve-
ment of the perforin/granzyme pathway in the mecha-
nism of MHC class I protection.
Results and Discussion
Protection of target cells from NK cell lysis by expression
of MHC class I molecules has been demonstrated in dif-
ferent experimental systems in human [11], mouse [12]
and rat [10,22]. In rat, several MHC class I genes have
been identified, i.e., RT1.A, RT1.C and RT1.E [23]. It has
been shown that transfection of RT1.A and RT1.C protects
target cells from lysis by NK cells [10]. However, other
data indicate that RT1.A molecules inhibit NK cells,
whereas RT1.C region molecules activate natural killing
[24,25]. Masking of RT1.A, RT1.C, or both alleles on target
cells with allele-specific mAbs, has no effect on lysis by NK
cells [26]. In view of these facts, mAb OX18 was chosen to
investigate the mechanism of MHC class I protection of
CC531s target cells from hepatic NK cell-mediated killing.
It has been found that (i) mAb OX18 binds total rat MHC
class I [27], (ii) masking of MHC class I molecules on tar-
get cells by mAb OX18 or F(ab')2 fragments of OX18 en-
hances the syngeneic target cell cytolysis by rat NK cells
[22], and (iii) the enhanced NK cell-mediated target lysis
by mAb OX18 is not caused by antibody dependent cellu-
lar cytotoxicity (ADCC) [22].
The expression of MHC class I molecules on CC531s cells
was examined by flow cytometry. In agreement with a pre-
vious study [22], CC531s cells expressed MHC class I mol-
ecules (data not shown). The mAb CC52, used as a
negative control during functional assays, was shown to
bind to CC531s cells, as has also been shown previously
[28] (data not shown). When CC531s cells were preincu-
bated with mAb OX18 against MHC class I molecules, the
hepatic NK cell-mediated cytolysis against CC531s cells
was increased in comparison with the lysis of untreated or
control mAb treated tumour cells (Fig. 1A). Similarly, the
preincubation of CC531s cells with mAb OX18 increased
fragmented DNA (apoptosis) in CC531s cells when coin-
cubated with hepatic NK cells (Fig. 1B). CC531s cells
showed the typical morphological characteristics of apop-
tosis such as nuclear fragmentation, chromatin condensa-
tion (Fig. 2A), blebbing, and rounding up (Fig. 2B), when
they were coincubated with hepatic NK cells. When
CC531s cells were pretreated with mAb OX18, the
number of apoptotic CC531s cells increased (Figs.
2C,2D,2G). It has been reported that anti-MHC class I an-
tibody alone can induce apoptosis in cancer cells [29]. In
order to address the question whether the enhanced apop-
tosis and cytolysis in CC531s cells was induced by the
binding of mAb OX18, CC531s cells were incubated with
mAb OX18 alone. After 3, 24 or 48 hours of incubation,
no apoptosis or cytolysis in CC531s cells was observed
(data not shown). This is the first time it is shown that, be-
sides cytolysis, MHC class I molecules protect cancer cells
from apoptosis induced by NK cells. This is relevant be-
cause it has been suggested that in vitro assays quantifying
effector cell-mediated apoptosis, but not cytolysis, are in
accordance with in vivo results [13].
To address the mechanism of protection of MHC class I
on CC531s cells, we used several approaches to assess the
granule exocytosis pathway: granzyme inhibition by DCI,
Ca2+ chelation by EGTA and caspase inhibition by Z-VAD-
FMK.
When hepatic NK cells were preincubated with DCI, a
granzyme inhibitor in intact cells [30], hepatic NK cell-
mediated CC531s cytolysis was largely inhibited (Fig. 3A)
and apoptosis was completely inhibited in the OX18-Comparative Hepatology 2002, 1 http://www.comparative-hepatology.com/content/1/1/2
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Figure 1
Effect of anti-MHC I mAb OX18 on hepatic NK cell-mediated CC531s cell cytolysis (A, 51Cr release) and apop-
tosis (B, DNA fragmentation). (A), 51Cr-labeled CC531s cells were incubated at an E:T ratio of 10:1 with freshly isolated
hepatic NK cells for 18 hours. Cytolysis was measured in a 51Cr-release assay. (B), [3H]-TdR labeled CC531s cells were incu-
bated at an E:T ratio of 10:1 with hepatic NK cells for 3 hours. Apoptosis was measured in a quantitative DNA fragmentation
assay. ConAb, control antibody. *p < 0.05, **p < 0.01 vs. the treatment with medium only (LSD test).
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Figure 2
Hepatic NK cell-induced apoptosis in CC531s cells as observed by fluorescence microscopy (A, C, E) and light
microscopy (B, D, F). CC531s cells were coincubated with hepatic NK cells at an E:T ratio of 10:1 for 3 hours. Cells were
stained with Hoechst 33342/propidium iodide. The thick arrows indicate apoptotic CC531s cells with fragmented nuclei. The
small cells are hepatic NK cells (thin arrows indicate examples). (A, B), Coincubation of CC531s cells with hepatic NK cells in
medium. (C, D), CC531s cells were pretreated with anti-MHC I mAb OX18. (E, F), CC531s cells were pretreated with anti-
MHC I mAb OX18 and hepatic NK cells were pretreated with DCI. The number of apoptotic CC531s cells dramatically
decreased. Bar = 10 µm. (G), The percentage of apoptotic CC531s cells was determined in preparations by counting at least
300 cells per sample. EGTA was present during the coincubation. *p < 0.05, **p < 0.01 vs. the corresponding control (LSD
test).Comparative Hepatology 2002, 1 http://www.comparative-hepatology.com/content/1/1/2
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Figure 3
Effect of DCI and EGTA on anti-MHC I mAb OX18 enhanced cytolysis (A, 51Cr release) and apoptosis (B,
DNA fragmentation) of CC531s cells by hepatic NK cells. CC531s cells were pretreated with mAb OX18 and hepatic
NK cells were pretreated with DCI. EGTA was present during the coincubation. (A), Cytolysis was determined by a 18 hour
51Cr-release assay. (B), Apoptosis was determined by a 3 hour quantitative DNA fragmentation assay. The E:T ratio was 10:1.
**p < 0.01 vs. the corresponding control (LSD test).
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treated and untreated CC531s cells (Fig. 3B and Figs.
2E,2F and 2G).
The perforin/granzyme pathway is Ca2+-dependent, in-
volving extracellular Ca2+ at three distinct steps: (i) gran-
ule exocytosis; (ii) binding of secreted perforin to the
membrane of target cells; and (iii) perforin polymerisa-
tion [5]. When extracellular Ca2+ was chelated by EGTA
during the co-incubation, the anti-MHC class I mAb-en-
hanced cytolysis and apoptosis of CC531s cells by hepatic
NK cells was completely inhibited (Figs. 2, 3).
The results obtained by granzyme inhibition and Ca2+
chelation strongly suggest the involvement of the per-
forin/granzyme pathway in the anti-MHC I mAb OX18
enhanced apoptosis and cytolysis. In order to verify these
results, we made use, in a separate series of experiments,
of the pan-caspase inhibitor Z-VAD-FMK. It has been
shown that in several apoptotic pathways, including the
perforin/granzyme pathway and the FasL pathway, DNA
fragmentation is caspase dependent. On the other hand,
cytolysis is also caspase dependent in the FasL pathway,
but caspase independent in the perforin/granzyme path-
way [31–33]. As a consequence, this caspase independent
cytolysis induction can be used to characterise the per-
forin/granzyme pathway. Indeed, when Z-VAD-FMK was
present during the coincubation of CC531s cells with he-
patic NK cells, the OX18 enhanced apoptosis was com-
pletely inhibited, while cytolysis was not inhibited at all
(Fig. 4). Fragmentation of the nucleus and condensation
of the chromatin were also inhibited (data not shown).
Conclusions
MHC class I expression protects colon carcinoma cells
from apoptosis and cytolysis induced by hepatic NK cells,
by blocking the perforin/granzyme pathway. This mecha-
nism of immune escape could possibly contribute to the
incomplete killing by hepatic NK cells of arriving colon
carcinoma cells in the liver sinusoids, resulting in the for-
mation of liver metastases.
Materials and Methods
Isolation and purification of hepatic NK cells
Hepatic NK cells were isolated and purified from 3- to 5-
month old male Wag/Rij rats (RT1u, a Wistar-derived in-
bred strain, Harlan, The Netherlands) according to the
method described before [34]. The purity of the isolated
hepatic NK cells was at least 90%, as evaluated by light mi-
croscopy using May-Giemsa staining cytospins and by
flow cytometric analysis using mAb 3.2.3, which recognis-
es CD161A molecules on the surface of rat NK cells [35].
The viability of the recovered cells was more than 95%, as
determined by trypan blue exclusion. The procedures
used in this study were approved by the local ethical com-
mittee (license no. LA1230212).
Tumour cell line
CC531s, a dimethylhydrazine-induced colon carcinoma
of Wag/Rij rats [36], was maintained in culture medium
RPMI-1640 (Gibco, Life Technologies, Gent, Belgium),
supplemented with 10% fetal calf serum (Eurobiochem,
Bierges, Belgium), penicillin (100 U/ml), streptomycin
(100 µg/ml), and glutamin (0.2 mM) (Gibco, Life Tech-
nologies, Gent, Belgium).
Reagents and antibodies
3,4-dichloroisocoumarin (DCI) and ethylene glycol-
bis(β-aminoethyl ether)-N, N-tetraacetic acid (EGTA),
were purchased from ICN (Asse-Relegem, Belgium). The
monoclonal antibody (mAb) OX18 (anti-rat MHC class I,
IgG1) [27] was purchased from ECACC (Porton Down,
Salisbury, UK). MAb CC52 (IgG1) [28] was developed in
the Department of Surgery and Pathology, Leiden Univer-
sity Medical Center, The Netherlands [37]. Z-Val-Ala-
Asp(OMe)-fluoromethylketone (Z-VAD-FMK) was ob-
tained from Bachem (Bubendorf, Switzerland).
Flow cytometry
The expression of MHC class I molecules on the CC531s
cells was determined by one-colour flow cytometric anal-
ysis, as described previously [38]. Briefly, 0.5 × 106 cells
were incubated (30 minutes, 4°C) with the primary anti-
body OX18. Cells were then washed three times with cold
phosphate-buffered saline (PBS), containing 1% bovine
serum albumin and 0.02% sodium azide. Subsequently,
cells were incubated with FITC-conjugated antimouse
IgG1 (Gilbertsville, PA). After incubation and washing,
cells were fixed with 2% paraformaldehyde in PBS and an-
alysed (FACSort; Becton Dickinson, Mountain View, CA,
USA). Isotype-matched irrelevant antibody was used as a
negative control.
Quantitative DNA fragmentation assay
DNA fragmentation in the CC531s cells was determined
as described previously [20]. In short, [methyl-3H]thymi-
dine ([3H]-TdR) labeled CC531s cells were preincubated
with the mAb OX18 (final concentration was 10 µg/ml)
for 15 minutes, at room temperature, and freshly isolated
hepatic NK cells were preincubated with 50 µM DCI for 30
minutes. It was shown that mAb CC52 binds to CC531s
cells [28] and is used in this study as a negative control in
the functional assays. The cells were then washed twice.
EGTA (final concentration was 5 mM) and Z-VAD-FMK
(final concentration 80 µM) were present during coincu-
bation. The hepatic NK cells (105 cells in 100 µl) and
CC531s cells (104 cells in 100 µl) were placed in triplicate
in 1.5 ml microcentrifuge tubes. After 3 hours coincuba-
tion and centrifugation, the incubation medium was re-
moved from the tubes. Subsequently, the pelleted cells
were lysed. The lysates were ultracentrifuged (10,000 g for
15 minutes at 4°C) to separate fragmented DNA from in-Comparative Hepatology 2002, 1 http://www.comparative-hepatology.com/content/1/1/2
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Figure 4
Effect of the pan caspase inhibitor Z-VAD-FMK on anti-MHC I mAb OX18 enhanced cytolysis (A, 51Cr release)
and apoptosis (B, DNA fragmentation). Z-VAD-FMK was present during coincubation. CC531s cells were incubated at
an E:T ratio of 10:1 with hepatic NK cells for 18 h (51Cr release) or 3 h (DNA fragmentation). **p < 0.01 vs. the corresponding
control (LSD test).
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tact DNA. Radioactivity (cpm) in the incubation medium,
in the 10,000 g supernatant and in the 10,000 pellet was
determined in a β counter (Beckman, Fullerton, CA, USA).
The percentage of fragmented DNA was calculated using
the following formula:
in which: cpmfr = the radioactivity in the incubation me-
dium plus the cpm in the 10,000 g supernatant; cpmtotal
= cpmfr + radioactivity in the 10,000 g pellet; exp = exper-
imental (target cells with effector cells); spont = spontane-
ous (target cells and medium only).
Hoechst 33342/propidium iodide staining
CC531s cells and freshly isolated hepatic NK cells were
treated as mentioned above. CC531s cells (104 cells in
100 µl), were coincubated with hepatic NK cells (105 cells
in 100 µl) in a flat-bottom 96-multiwell plate, for 3 hours
at 37°C. After coincubation, nuclei of the cells were
stained with Hoechst 33342 and propidium iodide, as de-
scribed previously [20]. Preparations were studied with a
Leica DM IRB/E inverted fluorescence microscope (Leica,
Heidelberg, Germany) with ultraviolet excitation, at 340
to 380 nm. The images were recorded and the number of
apoptotic CC531s cells was determined by the character-
istic morphological changes of the apoptotic nucleus, i.e.,
condensation of chromatin and nuclear fragmentation.
CC531s cells, not coincubated with hepatic NK cells, were
used as a control. The fragmented nuclei were counted in
at least 300 cells in each preparation and the percentage of
apoptotic CC531s cells was calculated using the following
formula:
51Cr-release assay
Cytolysis was measured in a 18 hour 51Cr-release assay us-
ing 96-multiwell plates, as described previously [15].
Briefly, 51Cr-labeled CC531s cells and hepatic NK cells
were treated with the mAb or DCI or EGTA or Z-VAD-
FMK, as mentioned above. CC531s cells at a concentra-
tion of 104 cells/well were coincubated with hepatic NK
cells at an effector-to-target (E:T) ratio of 10:1 in a final
volume of 200 µl. After 18 hours coincubation, the super-
natant of each well was aspirated and radioactivity was de-
termined in a γ counter. The cpm usually ranged from
1200 cpm (spontaneous release) to 5000 cpm (maximal
release). Results were expressed as percentage of specific
lysis according to the formula:
in which: exp = experimental (target cells with effector
cells); spont = spontaneous (target cells and medium on-
ly); max = maximal, obtained after the addition of SDS
(1% final concentration). All data are triplicate determi-
nations.
Statistical analysis
Statistical analysis was performed by one-way ANOVA (n
= 3 in each group, unless otherwise indicated) with post-
hoc multiple comparison analysis made by LSD (the least-
significant difference) test, using SPSS statistical package
(SPSS Inc., Chicago, IL, USA). Variances were assumed to
be homogeneous. Statistically significant difference be-
tween two groups was considered at the level of p < 0.05.
List of abbreviations used
ADCC, antibody dependent cellular cytotoxicity; cpm,
counts per minute; DCI, 3,4-dichloroisocoumarin; EGTA,
ethylene glycol-bis(β-aminoethyl ether)-N, N-tetraacetic
acid; FasL, Fas ligand; mAb, monoclonal antibody; MHC,
major histocompatibility complex; NK, natural killer; Z-
VAD-FMK, Z-Val-Ala-Asp(OMe)-fluoromethylketone.
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